Scotiabank initiated coverage of Johnson & Johnson with an Outperform rating and $230 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- enGene price target raised to $10 from $4 at UBS
- FDA appoints Richard Pazdur as Director of CDER
- Halozyme: JNJ gets FDA approval for new indication of DARZALEX Faspro
- Johnson & Johnson announces FDA approval of DARZALEX FASPRO for HR-SMM
- FDA approves J&J’s Darzalex Faspro for high-risk smoldering multiple myeloma